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Abstract: Extended-cycle oral contraceptives (OCs) are increasing in popularity in the United 
States. A new extended-cycle OC that contains the lowest doses of ethinyl estradiol (EE) and 
levonorgestrel (LNG) + continuous EE throughout the cycle is now available. It provides 84 days 
of a low-dose, combined active pill containing levonorgestrel 100 µg and ethinyl estradiol 20 µg. 
Instead of 7 days of placebo following the active pills, the regimen delivers 7 days of ethinyl 
estradiol 10 µg. Existing studies reveal a similar efficacy and adverse effect profile compared 
with other extended-regimen OCs. Specifically, the unscheduled bleeding profile is similar to 
other extended-cycle OCs and improves with the increase in the duration of use. Although lower 
daily doses of hormonal exposure have potential benefit, to our knowledge, there are no pub-
lished studies indicating that this specific regimen offers a lower incidence of hormone-related 
side effects or adverse events. In summary, this new extended-cycle OC provides patients a 
low-dose, extended-regimen OC option without sacrificing efficacy or tolerability.
Keywords: continuous regimen, ethinyl estradiol, extended cycle, oral contraceptive
Background
In 1960, the US Food and Drug Administration (FDA) approved the first oral 
contraceptive (OC) Enovid®, which contained norethynodrel 10 mg and mestranol 
150 µg.1 Since the introduction of the earliest products, the US market has witnessed 
a continual evolution of the hormonal content and cycle regimen of OCs. The first 
major change in the OC dose occurred in the 1970s, when the ethinyl estradiol (EE) 
content has been decreased from 50 µg to 30–35 µg.2,3 After this decrease in the EE 
content, the incidence of venous thrombosis events decreased significantly among 
OC users.4 Subsequently, formulations containing EE 20 µg were developed, which 
did not further decrease major adverse events, but at least theoretically offered 
fewer estrogen-related side effects.5,6 Most of the currently prescribed OCs contain 
20–35 µg EE.6
A second major change in OCs was the alteration of the cycle regimen.   Traditional 
  dosing regimens emulated a 28-day menstrual cycle with 21 days of combined 
EE + progestin active pills and 7 days of placebo pills or a pill-free week. Monthly bleed-
ing is not necessary for contraceptive efficacy or safety reasons. Since there is no biologi-
cal basis for this original cycle regimen, several changes to the regimen were developed, International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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offering women the option of experiencing fewer menses or 
improved side effects.7
One such change reduces the length of the active-pill-
free interval. In an attempt to decrease estrogen-related 
withdrawal symptoms associated with the traditional 7-day 
hormone-free interval, some newer OC regimens adapted 
a 24/4 dosing regimen, which provided 24 active pills and 
4 days of placebo pills, instead of the traditional 21 active 
pills followed by 7 days of placebo pills. Additionally, some 
evidence suggests that shortening the hormone-free interval 
results in greater ovarian suppression.8,9
Another recent major change in the cycle regimen is the 
introduction of extended-cycle OCs. The first dedicated prod-
ucts provide 84 days of active pills with a 7-day combined 
active-pill-free interval (placebo or EE alone). The major 
rationale for the use of extended-cycle OCs is potentially 
greater ovulation suppression. By reducing the frequency 
of withdrawal bleeding episodes, the extended-cycle OCs 
have been reported to treat menstrual-related symptoms, 
endometriosis, and dysmenorrhea.10 Extended-cycle OCs 
also offer the option of fewer overall withdrawal bleeding 
episodes, a benefit preferred by many women.11
Several extended-cycle OCs are currently   available 
(Table 1). In September 2003, the FDA approved an extended-
cycle OC in an 84/7 dosing regimen, EE 30 µg/levonorgestrel 
(LNG) 150 µg (Seasonale®; Duramed Pharmaceuticals, 
Cincinnati, Ohio). A patient takes 84 days of the combined 
active pill followed by 7 days of placebo pills. This regimen 
establishes 4 scheduled withdrawal bleeding episodes per 
year.12 Subsequently, in May 2006, the FDA approved a 
variation of this product (Seasonique®; Duramed Pharma-
ceuticals), with the same combined active pill containing 
LNG 150 µg and EE 30 µg, followed by 7 days of 10 µg EE 
pills, instead of placebo (EE 30 µg/LNG 150 µg + EE 10 µg). 
The rationale for the evolution of EE 30 µg/LNG 150 µg to 
EE 30 µg/LNG 150 µg + EE 10 mcg is that replacing the 
hormone-free interval with 7 days of EE provides the potential 
for greater   ovulation suppression, possibly leading to greater 
effectiveness. In addition, patients may experience less break-
through bleeding and fewer estrogen withdrawal symptoms, 
possibly improving compliance.13 The FDA later approved 
EE 20 µg/LNG 90 µg (Lybrel®; Wyeth Pharmaceuticals, 
Philadelphia, Pennsylvania) in 2007, which is administered as 
a combined active pill containing LNG 90 µg and EE 20 µg 
in a continuous fashion, 365 days per year.14,15
An OC formulation providing low-dose continuous EE 
received FDA approval in October 2008 (LoSeasonique®; 
Duramed Pharmaceuticals). This product delivers 84 days 
of EE 20 µg and LNG 100 µg, followed by 7 days of EE 
10 µg (EE 20 µg/LNG 100 µg + EE 10 µg). The reason 
for the development of this product was to offer patients a 
very low dose extended-cycle OC. The novel formulation 
provides the lowest dose of EE available in extended-cycle 
regimens thus far, combined with EE during the placebo 
week. The lowest dose of EE in OCs currently available in 
the United States is 20 µg, which is likely near the lowest 
dose required to produce contraceptive efficacy.16 Decreased 
estrogen exposure may result in fewer estrogen-related side 
effects, such as breast tenderness and nausea.5,17 A speculated 
disadvantage of the new formulation of EE 20 µg/LNG 
100 µg + EE 10 µg compared to EE 30 µg/LNG 150 µg + 
EE 10 µg is that decreasing the dosage of EE from 30 µg to 
20 µg could predispose to more unscheduled bleeding and 
spotting. With the introduction of EE 20 µg/LNG 100 µg + 
EE 10 µg, a very low-dose extended-cycle OC containing 
continuous EE, it is important to understand how this new 
product compares to the existing extended-cycle OCs with 
regard to pharmacology, efficacy, safety, tolerability, and 
patient satisfaction.
Pharmacology and 
pharmacodynamics
EE 20 µg/LNG 100 µg + EE 10 µg contains the well-
characterized progestin levonorgestrel [18,19-dinorpregn-
4-en-20-yn-3-one-13-ethyl-17-hydroxy-,(17α)-,(-)-], a 
second-generation progestin derived from 19-nortestos-
terone. The oral bioavailability of LNG is approximately 
90%–100% because the drug is not subject to first-pass 
metabolism. The volume of distribution of LNG is 1.8 L/kg. 
LNG is 97.5%–99% bound to sex hormone–binding protein 
and serum albumin.18
EE 20 µg/LNG 100 µg + EE 10 µg also contains EE 
19-norpregna-1,3,5 (10)-trien-20-yne-3, 17-diol,(17α). EE 
is the orally active and the most common estrogen in current 
Table 1 extended-cycle oral contraceptives
Formulation Pill regimen
ee 30 µg/LNG 150 µg 84 days combined active pill,  
7 days placebo pill
ee 30 µg/LNG 150 µg + ee 10 µg 84 days combined active pill 
7 days ee 10 µg
ee 20 µg/LNG 100 µg + ee 10 µg 84 days combined active pill, 
 7 days ee 10 µg
ee 20 µg/LNG 90 µg Daily combined active pill, 
1 withdrawal bleeding  
episode per year
Abbreviations: ee, ethinyl estradiol; LNG, levonorgestrel.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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OCs. The bioavailability of EE is only approximately 43% 
because it is subject to first-pass metabolism. The volume 
of distribution of EE is 4.3 L/kg. EE is 95%–97% bound to 
serum albumin.18
The mechanism of action of the combination of LNG and 
EE involves (1) ovulation suppression by inhibiting follicle 
stimulating hormone (FSH) and luteinizing hormone (LH); 
(2) cervical mucus changes that inhibit sperm penetration; and 
(3) endometrial changes that reduce the chances of successful 
implantation.16 Since EE specifically causes the suppression of 
FSH, the additional 7 days of EE potentially results in greater 
ovulation suppression. EE also helps stabilize the endometrium 
and may potentially decrease intermenstrual bleeding.
Efficacy
A key question with the introduction of a new OC product is 
whether it confers similar efficacy to other OCs in prevent-
ing pregnancy. To evaluate the contraceptive efficacy of EE 
20 µg/LNG 100 µg + EE 10 µg, Kroll et al19 conducted a 
multicenter, open-label clinical trial at 56 sites throughout 
the United States. Of the 2,185 women aged 18–40 years 
recruited to participate, 1,249 participants completed the 
12-month study. The Pearl index among all participants 
was 2.74 (95% CI, 1.92–3.78), based on 36 pregnancies that 
occurred after the onset of treatment and within 14 days of 
last combined active pill in women aged 18–35 years. The 
Pearl index among compliant participants was 1.73; 22 preg-
nancies occurred during the treatment among women aged 
18–35 years. The Pearl index of EE 20 µg/LNG 100 µg + 
EE 10 µg was slightly higher but similar to EE 30 µg/LNG 
150 µg (0.60), EE 30 µg/LNG 150 µg +EE 10 µg (1.2), and 
continuous EE 20 µg/LNG 90 µg (1.19).13,17,20 Overall, the 
efficacy of EE 20 µg/LNG 100 µg + EE 10 µg compared with 
the extended-cycle and cyclic OCs is similar.21
Safety
In their study, Kroll et al19 characterized the safety profile 
of EE 20 µg/LNG 100 µg + EE 10 µg in 1,249 participants. 
The most frequent adverse events were headaches (33%), 
nasopharyngitis (16%), and dysmenorrhea (11%). No venous 
thromboembolic events were reported during the study. 
The study population experienced increases in the levels 
of cholesterol, low-density lipoprotein, and triglycerides, 
but these increases were not clinically significant. Similar 
adverse events were reported in a safety and efficacy study 
of EE 30 µg/LNG 150 µg + EE 10 µg: intermenstrual bleed-
ing (11.5%), nasopharyngitis (7.2%), sinusitis (6.5%), and 
menorrhagia (5.8%).13 EE 20 µg/LNG 100 µg + EE 10 µg 
carries a similar adverse event profile compared with other 
extended-cycle and cyclic OCs.21
Tolerability
The major tolerability concern in prescribing extended-cycle 
OCs is unscheduled bleeding. Comparison of unscheduled 
bleeding between EE 30 µg/LNG 150 µg + EE 10 µg and 
EE 30 µg/LNG 150 µg is important, since one rationale 
for replacing the placebo week with EE was to potentially 
reduce the rate of unscheduled bleeding. In a retrospective 
cross-study analysis, Kaunitz et al22 found that unscheduled 
bleeding decreased more quickly with EE 30 µg/LNG 
150 µg + EE 10 µg compared with EE 30 µg/LNG 150 µg. 
Significant differences in scheduled bleeding were noted at 
each measured interval, with less bleeding experienced in 
EE 30 µg/LNG 150 µg + EE 10 µg users.
The unscheduled bleeding profile with EE 20 µg/LNG 
100 µg + EE 10 µg approximates that of other extended-
cycle OCs. In a multicenter, open-label study, Kroll et al19 
specifically studied unscheduled bleeding. Different types of 
bleeding were defined as follows: (1) bleeding was defined as 
vaginal bleeding that required use of sanitary pads, tampons, or 
both; (2) spotting was defined as vaginal bleeding that did not 
require use of sanitary pads, tampons, or both; (3) unscheduled 
bleeding was defined as spotting that occurred during the 84 
days of active combination pills; (4) unscheduled bleeding/
withdrawal bleeding was that occurring during the 7 days of 
EE-only pills. Intermenstrual bleeding or spotting decreased 
with time with both EE 20 µg/LNG 100 µg + EE 10 µg and 
EE 30 µg/LNG 150 µg + EE 10 µg, as shown in Table 2. 
The percentage of women who experienced intermenstrual 
bleeding or spotting decreased from the first 91-day treatment 
cycle to the fourth 91-day treatment cycle. In addition, the 
percentage of women who experienced a more than 20 days 
of intermenstrual bleeding or spotting declined between the 
first and the fourth treatment cycles.
The percentage of women who experienced intermen-
strual bleeding with EE 20 µg/LNG 100 µg + EE 10 µg 
compared with EE 30 µg/LNG 150 µg + EE 10 µg is also 
shown in Table 2. In a multicenter, open-label clinical 
study by Anderson et al,13 1,006 women who were taking 
EE 30 µg/LNG 150 µg + EE 10 µg over 12 months kept 
daily electronic diaries of compliance and bleeding. The 
percentage of women experiencing intermenstrual bleeding 
is slightly higher for EE 20 µg/LNG 100 µg + EE 10 µg com-
pared with EE 30 µg/LNG 150 µg + EE 10 µg, and there was 
a similar decrease in the percentage of women experiencing 
intermenstrual bleeding between cycle 1 and cycle 4.International Journal of Women’s Health 2010:2 submit your manuscript | www.dovepress.com
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Comparing the incidence of unscheduled bleeding for 
EE 20 µg/LNG 100 µg + EE 10 µg with EE 20 µg/LNG 
90 µg is difficult, given the difference in cycle regimen. To 
date, there is no published study comparing unscheduled 
EE 20 µg/LNG 100 µg + EE 10 µg with EE 20 µg/LNG 
90 µg. Unscheduled bleeding for EE 20 µg/LNG 90 µg has 
been studied independently. Teichmann et al17 conducted 
a randomized, open-label trial comparing EE 20 µg/LNG 
90 µg (n = 331) with a 21-day cyclic EE 20 µg/LNG 100 µg 
(n = 318). During the third month, 69.0% (n = 194) of EE 
20 µg/LNG 90 µg users reported spotting, bleeding, or both. 
During the 12th month, 47.1% (n = 99) patients reported spot-
ting, bleeding, or both. Overall, the incidence of unscheduled 
bleeding at the end of 1 year’s use was similar but higher for 
EE 20 µg/LNG 90 µg (21%) compared with the 21-day cyclic 
EE 20 µg/LNG 100 µg (12%). These findings on bleeding 
patterns are similar to the data on EE 20 µg/LNG 100 µg + 
EE 10 µg because the percentage of women who experience 
unscheduled bleeding decreases with time. A study compar-
ing the incidence of unscheduled bleeding of EE 20 µg/LNG 
100 µg + EE 10 µg with a 21-day cyclic regimen has not 
been published.
Patient satisfaction
The extended-cycle OCs have similar compliance rates 
compared with 28-day cyclic OCs.21 The discontinuation 
rate for EE 20 µg/LNG 100 µg + EE 10 due to an adverse 
event was 11.6%. The discontinuation rate partly attributed 
to the unscheduled bleeding was 9.6%.19 In comparison, the 
discontinuation rate for EE 30 µg/LNG 150 µg + EE 10 µg 
due to an adverse event was 16%, including intermenstrual 
bleeding, menorrhagia, increased weight, and mood swings.13 
The discontinuation rates for other OCs are similar between 
28-day and extended-cycle regimens. In addition, the discon-
tinuation rates for other OC agents, specifically for bleeding 
problems, are comparable between these regimens.21
Conclusion
The major potential benefit of EE 20 µg/LNG 100 µg + EE 
10 µg compared with the other available extended-cycle 
OCs is the lower hormonal exposure, which may result in 
fewer adverse effects, such as breast tenderness or nausea. 
However, no published study has specifically compared the 
estrogen adverse effect profile of EE 20 µg/LNG 100 µg + EE 
10 µg extended-cycle OCs containing 30 µg EE. The lower 
hormonal exposure could theoretically confer a lower risk 
of major adverse events, such as venous thromboembolism, 
but no study documents such a decrease of adverse events.21 
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Furthermore, it is critically important to understand that the 
absolute risk of major adverse events with all low-dose OCs 
is exceedingly low, so using the lowest 20 µg dose of EE does 
not offer a clinical advantage for this purpose. It is similarly 
unclear whether lowering the LNG dosage is beneficial; no 
study has specifically investigated any short- or long-term 
benefit of LNG 100 µg when compared with higher doses, 
such as 150 µg.
Although more long-term studies should investigate the 
effects of lower hormonal exposure with EE 20 µg/LNG 
100 µg + EE 10 µg and compare this drug with other extended-
cycle OCs, sufficient information is available to recommend 
EE 20 µg/LNG 100 µg + EE 10 µg to patients as an option 
for an extended-cycle OC. EE 20 µg/LNG 100 µg + EE 10 µg 
provides similar efficacy compared with other extended-cycle 
OCs. The unscheduled bleeding or spotting per cycle for EE 
20 µg/LNG 100 µg + EE 10 µg is similar to EE 30 µg/LNG 
150 µg + EE 10 µg, which uses higher daily doses of estrogen 
and progestin. The unscheduled bleeding or spotting with EE 
20 µg/LNG 100 µg + EE 10 µg decreases with the increase 
of number of cycles, similar to EE 30 µg/LNG 150 µg + EE 
10 µg. Discontinuation rates are similar to those of other 
extended-cycle OCs. With regard to usage, women may choose 
EE 20 µg/LNG 100 µg + EE 10 µg because it offers both an 
extended-cycle regimen and less hormonal exposure, even 
though the clinical benefits of this lowered exposure are not 
clearly established. Overall, EE 20 µg/LNG 100 µg + EE 10 µg 
offers an option for safe, effective extended-cycle OC use.
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